JP7165995B2 - 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療 - Google Patents

細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療 Download PDF

Info

Publication number
JP7165995B2
JP7165995B2 JP2019544812A JP2019544812A JP7165995B2 JP 7165995 B2 JP7165995 B2 JP 7165995B2 JP 2019544812 A JP2019544812 A JP 2019544812A JP 2019544812 A JP2019544812 A JP 2019544812A JP 7165995 B2 JP7165995 B2 JP 7165995B2
Authority
JP
Japan
Prior art keywords
antibody
antibodies
antigen
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019544812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508655A5 (https=
JP2020508655A (ja
Inventor
カルツォーネ，フランク，ジェイ
ヤン，ハイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remd Biotherapeutics Inc
Original Assignee
Remd Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remd Biotherapeutics Inc filed Critical Remd Biotherapeutics Inc
Publication of JP2020508655A publication Critical patent/JP2020508655A/ja
Publication of JP2020508655A5 publication Critical patent/JP2020508655A5/ja
Application granted granted Critical
Publication of JP7165995B2 publication Critical patent/JP7165995B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019544812A 2017-02-21 2018-01-05 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療 Active JP7165995B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762461560P 2017-02-21 2017-02-21
US62/461,560 2017-02-21
PCT/US2018/012545 WO2018156250A1 (en) 2017-02-21 2018-01-05 Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)

Publications (3)

Publication Number Publication Date
JP2020508655A JP2020508655A (ja) 2020-03-26
JP2020508655A5 JP2020508655A5 (https=) 2021-02-12
JP7165995B2 true JP7165995B2 (ja) 2022-11-07

Family

ID=63254023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019544812A Active JP7165995B2 (ja) 2017-02-21 2018-01-05 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療

Country Status (5)

Country Link
US (1) US11319372B2 (https=)
EP (1) EP3585430A4 (https=)
JP (1) JP7165995B2 (https=)
CN (1) CN110545844A (https=)
WO (1) WO2018156250A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
DK3551660T5 (da) 2016-12-07 2024-09-02 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
JP7173993B2 (ja) 2017-05-19 2022-11-17 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210108978A (ko) 2018-12-21 2021-09-03 오제 이뮈노테라프틱스 이작용성 항-pd-1/il-7 분자
CA3122773A1 (en) 2018-12-26 2020-07-02 Xilio Development, Inc. Anti-ctla4 antibodies and methods of use thereof
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
WO2020163817A1 (en) * 2019-02-08 2020-08-13 Prothena Biosciences Limited Antibodies recognizing tau
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
WO2021170750A1 (en) 2020-02-28 2021-09-02 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2021250594A1 (en) 2020-06-11 2021-12-16 Nantbio, Inc. Anti-ctla4 monoclonal antibodies and chimeric antigen receptors
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
CN113244389B (zh) * 2021-07-06 2021-09-17 诺赛联合(北京)生物医学科技有限公司 一种TILs细胞制备方法及在肿瘤治疗的用途
WO2023134771A1 (zh) * 2022-01-17 2023-07-20 上海君实生物医药科技股份有限公司 抗ctla-4抗体药物组合物及其用途
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
EP4687991A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2025140296A1 (zh) * 2023-12-26 2025-07-03 上海宏成药业有限公司 抗dll3抗体或其抗原结合片段及其用途
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026012032A1 (en) * 2024-07-10 2026-01-15 Wuxi Biologics (Shanghai) Co., Ltd. Antibodies against integrin and uses thereof
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537226A (ja) 1998-12-23 2002-11-05 ファイザー インコーポレーテッド Ｃｔｌａ−４に対するヒトモノクローナル抗体
JP2014512809A (ja) 2011-03-09 2014-05-29 アンチトープ・リミテッド ヒト化抗ｃｔｌａ４抗体
US20160237154A1 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7494779B2 (en) * 2004-06-14 2009-02-24 Li-Te Chin Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
EP2749571A3 (en) 2006-01-10 2014-08-13 ZymoGenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
CN101628940B (zh) * 2008-07-15 2011-11-23 中国科学院生物物理研究所 一种单克隆抗体及其应用
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN104292334B (zh) * 2014-04-25 2018-11-27 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537226A (ja) 1998-12-23 2002-11-05 ファイザー インコーポレーテッド Ｃｔｌａ−４に対するヒトモノクローナル抗体
JP2014512809A (ja) 2011-03-09 2014-05-29 アンチトープ・リミテッド ヒト化抗ｃｔｌａ４抗体
US20160237154A1 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mengnan He et al.，Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies，Oncotarget，2017年05月19日，Vol.8, No.40，pp.67129-67139

Also Published As

Publication number Publication date
EP3585430A4 (en) 2020-12-09
EP3585430A1 (en) 2020-01-01
JP2020508655A (ja) 2020-03-26
CN110545844A (zh) 2019-12-06
WO2018156250A1 (en) 2018-08-30
US11319372B2 (en) 2022-05-03
US20200055937A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
JP7165995B2 (ja) 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療
JP7128529B2 (ja) プログラム死リガンド－１（ｐｄ－ｌ１）に結合する抗体を使用する免疫
CA2919790C (en) Anti-cxcr4 antibodies and antibody-drug conjugates
US11242398B2 (en) Anti-OX40 antibodies and methods of activating OX40
JP7122758B2 (ja) プログラム死－１（ｐｄ－１）に結合する抗体を使用する免疫療法
EP4281484B1 (en) Anti-her-2/trop-2 constructs and uses thereof
US20260109770A1 (en) C-c chemokine receptor type 8 (ccr8) antagonist antibodies
WO2021216832A1 (en) Chemokine receptor 4 (cxcr4) antagonist antibodies
CN115803062B (zh) 滋养层细胞表面抗原2(trop-2)抗体
US12617857B2 (en) Chemokine receptor 4 (CXCR4) antagonist antibodies
CN112203685A (zh) 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220713

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220713

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220802

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221018

R150 Certificate of patent or registration of utility model

Ref document number: 7165995

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150